{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:23:14Z","timestamp":1790677394549,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pompe disease is a rare, progressive metabolic myopathy. The aim of this study is to investigate the associations of physical outcomes with patient-reported outcome measures (PROMs) in late-onset Pompe disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included 121 Dutch adult patients with Pompe disease.<\/jats:p>\n                    <jats:p>Physical outcomes comprised muscle strength (manual muscle testing using Medical Research Council [MRC] grading, hand-held dynamometry [HHD]), walking ability (6-min walk test [6MWT]), and pulmonary function (forced vital capacity [FVC] in upright and supine positions).<\/jats:p>\n                    <jats:p>PROMs comprised quality of life (Short Form 36 health survey [SF-36]), participation (Rotterdam Handicap Scale [RHS]) and daily-life activities (Rasch-Built Pompe-Specific Activity [R-PAct] Scale).<\/jats:p>\n                    <jats:p>Analyses were cross-sectional: the time-point before, and closest to, start of Enzyme Replacement Therapy was chosen. Associations between PROMs and physical outcomes were investigated using linear regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>RHS and R-PAct scores were better in patients with higher FVC supine and upright, HHD, MRC and 6MWT scores, accounting for the effect of sex, disease duration, use of wheelchair and ventilator support. While the SF-36 Physical Component Summary (PCS) was correlated positively with FVC upright, HHD, MRC and 6MWT scores, there was no significant relationship between the SF-36 Mental Component Summary (MCS) and any of the physical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Participation, daily-life activities, and the physical component of quality of life of adult Pompe patients are positively correlated to physical outcomes. This work serves as a first step towards assessing how changes over time in physical outcomes are related to changes in PROMs, and to define the minimal change in physical outcomes required to make an important difference for the patient.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-020-01469-7","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T02:02:39Z","timestamp":1599098559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Positive association between physical outcomes and patient-reported outcomes in late-onset Pompe disease: a cross sectional study"],"prefix":"10.1186","volume":"15","author":[{"given":"Meng","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni-Rosalina","family":"Andrinopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle E.","family":"Kruijshaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aglina","family":"Lika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurike","family":"Harlaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3359-1324","authenticated-orcid":false,"given":"Ans T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Rizopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine A. M. E.","family":"van der Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"1469_CR1","first-page":"3389","volume-title":"The metabolic and molecular bases of inherited disease","author":"R Hirschhorn","year":"2001","unstructured":"Hirschhorn R, Reuser AJ. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL, Valle D, Sly W, Childs B, Kinzler KW, et al., editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 3389\u2013420.","edition":"8"},{"issue":"15","key":"1469_CR2","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT van der Ploeg","year":"2010","unstructured":"van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N Engl J Med. 2010;362(15):1396\u2013406.","journal-title":"N Engl J Med"},{"issue":"6","key":"1469_CR3","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s10545-014-9728-1","volume":"37","author":"LJ Anderson","year":"2014","unstructured":"Anderson LJ, Henley W, Wyatt KM, Nikolaou V, Waldek S, Hughes DA, et al. Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study. J Inherit Metab Dis. 2014;37(6):945\u201352.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"1469_CR4","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s00415-011-6293-5","volume":"259","author":"C Angelini","year":"2012","unstructured":"Angelini C, Semplicini C, Ravaglia S, Bembi B, Servidei S, Pegoraro E, et al. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol. 2012;259(5):952\u20138.","journal-title":"J Neurol"},{"issue":"6","key":"1469_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10545-010-9201-8","volume":"33","author":"B Bembi","year":"2010","unstructured":"Bembi B, Pisa FE, Confalonieri M, Ciana G, Fiumara A, Parini R, et al. Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. J Inherit Metab Dis. 2010;33(6):727\u201335.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"1469_CR6","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s10545-012-9451-8","volume":"35","author":"C Regnery","year":"2012","unstructured":"Regnery C, Kornblum C, Hanisch F, Vielhaber S, Strigl-Pill N, Grunert B, et al. 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. J Inherit Metab Dis. 2012;35(5):837\u201345.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"1469_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","volume":"257","author":"S Strothotte","year":"2010","unstructured":"Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C, et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol. 2010;257(1):91\u20137.","journal-title":"J Neurol"},{"issue":"3","key":"1469_CR8","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","volume":"107","author":"AT Van der Ploeg","year":"2012","unstructured":"Van der Ploeg AT, Barohn R, Carlson L, Charrow J, Clemens PR, Hopkin RJ, et al. Open-label extension study following the late-onset treatment study (LOTS) of alglucosidase alfa. Mol Genet Metab. 2012;107(3):456\u201361.","journal-title":"Mol Genet Metab"},{"key":"1469_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1750-1172-7-73","volume":"7","author":"JM de Vries","year":"2012","unstructured":"de Vries JM, van der Beek NA, Hop WC, Karstens FP, Wokke JH, de Visser M, et al. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis. 2012;7:73.","journal-title":"Orphanet J Rare Dis"},{"issue":"23","key":"1469_CR10","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","volume":"89","author":"E Kuperus","year":"2017","unstructured":"Kuperus E, Kruijshaar ME, Wens SCA, de Vries JM, Favejee MM, van der Meijden JC, et al. Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study. Neurology. 2017;89(23):2365\u201373.","journal-title":"Neurology."},{"key":"1469_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1750-1172-8-49","volume":"8","author":"D Gungor","year":"2013","unstructured":"Gungor D, Kruijshaar ME, Plug I, D'Agostino RB, Hagemans ML, van Doorn PA, et al. Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis. 2013;8:49.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"1469_CR12","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/ene.13285","volume":"24","author":"AT van der Ploeg","year":"2017","unstructured":"van der Ploeg AT, Kruijshaar ME, Toscano A, Laforet P, Angelini C, Lachmann RH, et al. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol. 2017;24(6):768\u2013e31.","journal-title":"Eur J Neurol"},{"issue":"19","key":"1469_CR13","doi-asserted-by":"publisher","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","volume":"93","author":"L Harlaar","year":"2019","unstructured":"Harlaar L, Hogrel JY, Perniconi B, Kruijshaar ME, Rizopoulos D, Taouagh N, et al. Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease. Neurology. 2019;93(19):e1756\u2013e67.","journal-title":"Neurology"},{"issue":"9","key":"1469_CR14","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1212\/01.WNL.0000142597.69707.78","volume":"63","author":"ML Hagemans","year":"2004","unstructured":"Hagemans ML, Janssens AC, Winkel LP, Sieradzan KA, Reuser AJ, Van Doorn PA, et al. Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology. 2004;63(9):1688\u201392.","journal-title":"Neurology"},{"issue":"7","key":"1469_CR15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.nmd.2007.03.006","volume":"17","author":"ML Hagemans","year":"2007","unstructured":"Hagemans ML, Laforet P, Hop WJ, Merkies IS, Van Doorn PA, Reuser AJ, et al. Impact of late-onset Pompe disease on participation in daily life activities: evaluation of the Rotterdam handicap scale. Neuromuscul Disord. 2007;17(7):537\u201343.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"1469_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10545-015-9889-6","volume":"39","author":"D G\u00fcng\u00f6r","year":"2016","unstructured":"G\u00fcng\u00f6r D, Kruijshaar ME, Plug I, Rizopoulos D, Kanters TA, Wens SCA, et al. Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up. J Inherit Metab Dis. 2016;39(2):253\u201360.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"1469_CR17","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10545-014-9751-2","volume":"38","author":"JC van der Meijden","year":"2015","unstructured":"van der Meijden JC, Gungor D, Kruijshaar ME, Muir AD, Broekgaarden HA, van der Ploeg AT. Ten years of the international Pompe survey: patient reported outcomes as a reliable tool for studying treated and untreated children and adults with non-classic Pompe disease. J Inherit Metab Dis. 2015;38(3):495\u2013503.","journal-title":"J Inherit Metab Dis"},{"key":"1469_CR18","volume-title":"Aids to examination of the peripheral nervous system. Memorandum no. 45","author":"Medical Research Council","year":"1976","unstructured":"Medical Research Council. Aids to examination of the peripheral nervous system. Memorandum no. 45. London: Office HMsS; 1976."},{"issue":"3","key":"1469_CR19","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1136\/jnnp.54.3.244","volume":"54","author":"RJ van der Ploeg","year":"1991","unstructured":"van der Ploeg RJ, Fidler V, Oosterhuis HJ. Hand-held myometry: reference values. J Neurol Neurosurg Psychiatry. 1991;54(3):244\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1469_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","volume":"166","author":"American Thoracic Society Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories","year":"2002","unstructured":"American Thoracic Society Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5 Pt 1","key":"1469_CR21","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1164\/ajrccm.158.5.9710086","volume":"158","author":"PL Enright","year":"1998","unstructured":"Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med. 1998;158(5 Pt 1):1384\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"1469_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1183\/09041950.005s1693","volume":"16","author":"PH Quanjer","year":"1993","unstructured":"Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for steel and coal. Official statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5\u201340.","journal-title":"Eur Respir J Suppl"},{"issue":"4","key":"1469_CR23","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1164\/rccm.166.4.518","volume":"166","author":"American Thoracic Society\/European Respiratory Society","year":"2002","unstructured":"American Thoracic Society\/European Respiratory Society. ATS\/ERS statement on respiratory muscle testing. Am J Respir Crit Care Med. 2002;166(4):518\u2013624.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"1469_CR24","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473\u201383.","journal-title":"Med Care"},{"issue":"11","key":"1469_CR25","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S0895-4356(98)00097-3","volume":"51","author":"NK Aaronson","year":"1998","unstructured":"Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, et al. Translation, validation, and norming of the Dutch language version of the SF-36 health survey in community and chronic disease populations. J Clin Epidemiol. 1998;51(11):1055\u201368.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"1469_CR26","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/mus.10045","volume":"25","author":"IS Merkies","year":"2002","unstructured":"Merkies IS, Schmitz PI, Van Der Meche FG, Samijn JP, Van Doorn PA. Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies. Muscle Nerve. 2002;25(3):370\u20137.","journal-title":"Muscle Nerve"},{"issue":"3","key":"1469_CR27","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.nmd.2012.10.024","volume":"23","author":"NA van der Beek","year":"2013","unstructured":"van der Beek NA, Hagemans ML, van der Ploeg AT, van Doorn PA, Merkies IS. The Rasch-built Pompe-specific activity (R-PAct) scale. Neuromuscul Disord. 2013;23(3):256\u201364.","journal-title":"Neuromuscul Disord"},{"key":"1469_CR28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13023-015-0334-6","volume":"10","author":"TA Kanters","year":"2015","unstructured":"Kanters TA, Redekop K, Rutten-Van M\u00f6lken MPMH, Kruijshaar ME, G\u00fcng\u00f6r D, et al. A conceptual disease model for adult Pompe disease. Orphanet J Rare Dis. 2015;10:112.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"1469_CR29","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1007\/s00415-019-09401-1","volume":"266","author":"KI Berger","year":"2019","unstructured":"Berger KI, Kanters S, Jansen JP, Stewart A, Sparks S, An Haack K, et al. Forced vital capacity and cross-domain late-onset Pompe disease outcomes: an individual patient-level data meta-analysis. J Neurol. 2019;266(9):2312\u201321.","journal-title":"J Neurol"},{"issue":"1","key":"1469_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2105\/AJPH.87.1.38","volume":"87","author":"GI Kempen","year":"1997","unstructured":"Kempen GI, Ormel J, Brilman EI, Relyveld J. Adaptive responses among Dutch elderly: the impact of eight chronic medical conditions on health-related quality of life. Am J Public Health. 1997;87(1):38\u201344.","journal-title":"Am J Public Health"},{"key":"1469_CR31","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3389\/fonc.2019.00783","volume":"9","author":"G Ilie","year":"2019","unstructured":"Ilie G, Bradfield J, Moodie L, Lawen T, Ilie A, Lawen Z, et al. The role of response-shift in studies assessing quality of life outcomes among Cancer patients: a systematic review. Front Oncol. 2019;9:783.","journal-title":"Front Oncol"},{"issue":"11","key":"1469_CR32","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0277-9536(99)00047-7","volume":"48","author":"CE Schwartz","year":"1999","unstructured":"Schwartz CE, Sprangers MA. Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Soc Sci Med. 1999;48(11):1531\u201348.","journal-title":"Soc Sci Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01469-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01469-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01469-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T09:20:17Z","timestamp":1630660817000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01469-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1469"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01469-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-27192\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,3]]},"assertion":[{"value":"4 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All studies in this paper were approved by the ethics committee of the Erasmus MC University Medical Center and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from all participants prior to their inclusion.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A. van der Ploeg received funding for research, clinical trials and as an advisor from various industries working on ERT or next-generation therapies in the field of Pompe disease, other lysosomal storage diseases, and neuromuscular disorders under agreements with Erasmus MC University Medical Center and the relevant industry. N. van der Beek received funding for research and as advisor from various industries working on ERT or next-generation therapies in the field of Pompe disease under agreements with Erasmus MC University Medical Center and the relevant industry. The other authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"232"}}